Clinical Trials
6 trialsNCT05484622 2026-03-12
Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma
Servier
Phase 1 Active not recruiting
NCT07235748 2026-02-17
Drug-drug Interaction Study of Vorasidenib With Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, and Rosuvastatin in Healthy Adult Participants
Servier
Phase 1 Completed
NCT07240662 2026-01-09
VIOLETA
iOMEDICO AG
Recruiting
NCT06969352 2025-05-13
VICTORIA
Servier (Tianjin) Pharmaceutical Co. LTD.
Not yet recruiting
NCT04164901 2025-04-03
Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)
Servier
Phase 3 Active not recruiting
NCT05592743 2024-11-05
Vorasidenib Expanded Access Program
Servier
Approved for marketing